BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

NHS leaders are considering a phased rollout of the obesity injection tirzepatide (Mounjaro, Eli Lilly) because of potentially high demand. The National Institute for Health and Care Excellence (NICE) ...

NHS England has asked NICE to consider a slow phased rollout of tirzepatide for weight loss in primary care to avoid overwhelming GPs.

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...